Invicro, a Konica Minolta company and a leading provider of imaging biomarkers, core lab services and software for research and drug development appoints Evan Morris, Ph.D. as VP of Scientific Imaging Research, New Haven.
With more than 25 years of translational research experience and an ongoing appointment as a tenured, full professor at Yale University, Dr. Morris will further strengthen Invicro’s leading market position in molecular imaging. Dr. Morris will be based out of Invicro’s New Haven site, offering support and technical direction for translational research, core lab analysis, clinical operations and chemistry services.
“We are extremely pleased to have Evan join Invicro’s leadership team,” stated Dr. Roger Gunn, EVP of Quantitative Data Sciences for Invicro and Professor of Molecular Neuro Imaging at Imperial College London. “With his vast international experience in radiology and biomedical imaging, Evan will bring immediate value to our pharma customers by helping to accelerate disease diagnostics and drug discoveries through the delivery of translational and core lab imaging.”
Dr. Morris has been a professor of Radiology and Biomedical Imaging, Biomedical Engineering, and Psychiatry at Yale University for over 10 years focusing on functional brain imaging. Prior to Yale, Dr. Morris taught at Indiana University-Purdue University Indianapolis. Dr. Morris is an expert in tracer kinetic modeling which is used to translate standard emission images into parametric images of physiology, biochemistry and pharmacology. He has conducted over 100 invited lectures and educational seminars, has numerous peer reviewed publications, and has served as the lead investigator on many interdisciplinary NIH- and industry-sponsored research projects involving imaging and medications development for neuropsychiatric diseases and cancer.
“Over the years, I have had the pleasure of visiting and interacting with Invicro personnel at the New Haven, Boston, and London sites. I have always been impressed by their sophistication, professionalism, and enthusiasm for the work. I am greatly looking forward to working alongside my new Invicro colleagues and their pharma sponsors,” said Dr. Morris. “Working with industry and advising them on their research that supports the development of novel therapies will be extremely rewarding and a natural progression from my earlier work on more basic questions in imaging and kinetic modeling.”
Dr. Morris did his postdoctoral fellowship at Harvard Medical School after completing his MS and Ph.D. in Biomedical Engineer at Case Western Research University. Dr. Morris also holds SB degrees in Biology and Chemical Engineering from MIT.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now as part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, has inspired a strong and growing presence in the pre-clinical to late-phase clinical markets. For more information, visit www.invicro.com.
About Konica Minolta
Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and society—today and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customer’s most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrow’s issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/